236 related articles for article (PubMed ID: 11577818)
1. What is the "best" platinum: cisplatin, carboplatin, or oxaliplatin?
Lokich J
Cancer Invest; 2001; 19(7):756-60. PubMed ID: 11577818
[No Abstract] [Full Text] [Related]
2. Platinum compounds in the treatment of advanced breast cancer.
MartÃn M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacology of platinum compounds: differences between the three molecules and factors of interpatient variability].
Chatelut E
Bull Cancer; 2011 Nov; 98(11):1253-61. PubMed ID: 22024542
[TBL] [Abstract][Full Text] [Related]
4. Toxicity of platinum compounds.
Hartmann JT; Lipp HP
Expert Opin Pharmacother; 2003 Jun; 4(6):889-901. PubMed ID: 12783586
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.
Rixe O; Ortuzar W; Alvarez M; Parker R; Reed E; Paull K; Fojo T
Biochem Pharmacol; 1996 Dec; 52(12):1855-65. PubMed ID: 8951344
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacological study of an oxaliplatin and carboplatin combination in advanced malignancies.
Mita C; Chatelut E; Bekradda M; Soulié P; Canal P; Misset JL; Cvitkovic E; Bugat R
Ann Oncol; 2003 Dec; 14(12):1776-82. PubMed ID: 14630684
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of resistance and toxicity associated with platinating agents.
Rabik CA; Dolan ME
Cancer Treat Rev; 2007 Feb; 33(1):9-23. PubMed ID: 17084534
[TBL] [Abstract][Full Text] [Related]
8. Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines.
Kitada N; Takara K; Minegaki T; Itoh C; Tsujimoto M; Sakaeda T; Yokoyama T
Cancer Chemother Pharmacol; 2008 Sep; 62(4):577-84. PubMed ID: 18030470
[TBL] [Abstract][Full Text] [Related]
9. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress.
Bruno PM; Liu Y; Park GY; Murai J; Koch CE; Eisen TJ; Pritchard JR; Pommier Y; Lippard SJ; Hemann MT
Nat Med; 2017 Apr; 23(4):461-471. PubMed ID: 28263311
[TBL] [Abstract][Full Text] [Related]
10. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jun; (6):CD010885. PubMed ID: 24968257
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin-induced loss of phosphorylated heavy neurofilament subunit neuronal immunoreactivity in rat DRG tissue.
Jamieson SM; Subramaniam J; Liu JJ; Jong NN; Ip V; Connor B; McKeage MJ
Mol Pain; 2009 Nov; 5():66. PubMed ID: 19922644
[TBL] [Abstract][Full Text] [Related]
12. Analysis of cytotoxicities of platinum compounds.
Goodisman J; Hagrman D; Tacka KA; Souid AK
Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
[TBL] [Abstract][Full Text] [Related]
13. Toxicities of the platinum antineoplastic agents.
Markman M
Expert Opin Drug Saf; 2003 Nov; 2(6):597-607. PubMed ID: 14585068
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin, oxaliplatin, and carboplatin unequally inhibit in vitro mRNA translation.
Becker JP; Weiss J; Theile D
Toxicol Lett; 2014 Feb; 225(1):43-7. PubMed ID: 24275384
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity.
Taylor SE; Beck TL; Krivak TC; Zorn KK; Kelley JL; Edwards RP
Gynecol Oncol; 2014 Jul; 134(1):68-72. PubMed ID: 24769036
[TBL] [Abstract][Full Text] [Related]
16. Platinum derivatives: a multidisciplinary approach.
Gheorghe-Cetean S; Cainap C; Oprean L; Hangan A; Virag P; Fischer-Fodor E; Gherman A; Cainap S; Constantin AM; Laszlo I; Vlad C; Oprean R
J BUON; 2017; 22(3):568-577. PubMed ID: 28730758
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin is active in vitro against human melanoma cell lines: comparison with cisplatin and carboplatin.
Mohammed MQ; Retsas S
Anticancer Drugs; 2000 Nov; 11(10):859-63. PubMed ID: 11142694
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin in first-line therapy for advanced non-small-cell lung cancer.
Raez LE; Kobina S; Santos ES
Clin Lung Cancer; 2010 Jan; 11(1):18-24. PubMed ID: 20085863
[TBL] [Abstract][Full Text] [Related]
19. Glioblastoma treatment: bypassing the toxicity of platinum compounds by using liposomal formulation and increasing treatment efficiency with concomitant radiotherapy.
Charest G; Sanche L; Fortin D; Mathieu D; Paquette B
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):244-9. PubMed ID: 22284691
[TBL] [Abstract][Full Text] [Related]
20. Contributions of rat Ctr1 to the uptake and toxicity of copper and platinum anticancer drugs in dorsal root ganglion neurons.
Liu JJ; Kim Y; Yan F; Ding Q; Ip V; Jong NN; Mercer JF; McKeage MJ
Biochem Pharmacol; 2013 Jan; 85(2):207-15. PubMed ID: 23123662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]